Loading clinical trials...
Loading clinical trials...
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ruijin Hospital
NCT03922321 · Graves' Ophthalmopathy
NCT02535975 · Mild Graves' Ophthalmopathy
NCT02721992 · Graves' Ophthalmopathy, Hypercholesterolemia
NCT01056419 · Graves' Ophthalmopathy
NCT00430547 · Graves' Ophthalmopathy
Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital
Shanghai, Shanghai Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions